Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 31.10.2020 at 7:00 AM CET
Settings

Settings

Goto Application

1. WO1996040273 - CONJUGATES OF FERRITES AND OLIGONUCLEOTIDES, WHICH BOND SPECIFICALLY TO CERTAIN TARGET STRUCTURES

Publication Number WO/1996/040273
Publication Date 19.12.1996
International Application No. PCT/EP1996/002442
International Filing Date 05.06.1996
Chapter 2 Demand Filed 03.12.1996
IPC
A61K 49/18 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
49Preparations for testing in vivo
06Nuclear magnetic resonance (NMR) contrast preparations; Magnetic resonance imaging (MRI) contrast preparations
18characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
A61K 51/12 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51Preparations containing radioactive substances for use in therapy or testing in vivo
12characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
CPC
A61K 49/1857
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
49Preparations for testing in vivo
06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
18characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
1818particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
1821coated or functionalised microparticles or nanoparticles
1824coated or functionalised nanoparticles
1827having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
1851having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
1857the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
A61K 51/1241
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51Preparations containing radioactive substances for use in therapy or testing in vivo
12characterised by a special physical form, e.g. emulsion, microcapsules, liposomes ; , characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
1241particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
Applicants
  • SCHERING AKTIENGESELLSCHAFT [DE]/[DE]
  • NEXSTAR PHARMACEUTICALS, INC. [US]/[US]
Inventors
  • PFEFFERER, Detlev
  • KRESSE, Mayk
  • PLATZEK, Johannes
  • NIEDBALLA, Ulrich
  • GRIES, Heinz
  • RADÜCHEL, Bernd
  • GOLD, Larry
Common Representative
  • SCHERING AKTIENGESELLSCHAFT
Priority Data
08/476,11607.06.1995US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CONJUGATES OF FERRITES AND OLIGONUCLEOTIDES, WHICH BOND SPECIFICALLY TO CERTAIN TARGET STRUCTURES
(FR) CONJUGUES DE FERRITE ET D'OLIGONUCLEOTIDES QUI SE LIENT SPECIFIQUEMENT A CERTAINES STRUCTURES CIBLES
Abstract
(EN)
This invention relates to new oligonucleotide conjugates, which contain a coated chemically modified ferrite as signal-transmitting group, on which oligonucleotides are bound by connecting components. In this case, the oligonucleotides are modified in a way that prevents or at least significantly inhibits the degradation by naturally occurring nucleases. The oligonucleotide can bond specifically and with high bonding affinity on target structures and can thus have a specific diagnostic and/or therapeutic effect on the ferrite.
(FR)
Cette invention se rapporte à de nouveaux conjugués d'oligonucléotides contenant une ferrite revêtue et modifiée chimiquement servant de groupe émetteur de signaux, à laquelle les oligonucléotides se fixent par des composants de connexion. Dans ce cas, les oligonucléotides sont modifiés de façon à empêcher ou à réduire au moins de façon significative la dégradation due aux nucléases d'origine naturelle. L'oligonucléotide peut se lier spécifiquement et avec une très grande affinité de liaison aux structures cibles et peut donc produire un effet diagnostique et/ou thérapeutique particulier sur la ferrite.
Also published as
EP1996920793
Latest bibliographic data on file with the International Bureau